An innovative approach to treating bone tumors - starving cancer cells of the energy they need to grow - could one day provide an alternative to a commonly used chemotherapy drug without the risk of severe side effects, suggests a new study. Studying human cancer cells and mice, the researchers said that a two-drug combination targeting a tumor's energy sources could be as effective and less toxic than methotrexate, a long-used chemotherapy drug often given in high doses to treat osteosarcoma, a bone cancer. The study appears in the journal Cell Reports.
Osteosarcoma is the most common tumor of the bone in adults and children. It accounts for about 4% of all pediatric cancers and more than half of all pediatric bone cancers. Standard treatment for osteosarcoma includes surgery, radiation and a cocktail of chemotherapy drugs including high-dose methotrexate, which can cause liver and kidney damage.
"We are interested in developing therapies that kill cancer cells without harming healthy cells, potentially avoiding the sometimes severe side effects of traditional chemotherapy," said senior author. "In high doses, methotrexate can lead to liver failure and the need for kidney dialysis. We would like to get rid of the methotrexate in this regimen and replace it with a targeted metabolic therapy that would shorten the treatment, reduce the side effects and potentially eliminate the need for multiple hospitalizations."
The researchers studied an investigational drug called NCT-503, a member of a relatively new class of drugs called PHGDH inhibitors that have gained interest as potential metabolic therapies for cancer. Metabolic therapies target the chemical reactions that cancer cells perform to sustain life. This investigational drug prevents cancer cells from manufacturing the amino acid serine, a source of energy that fuels cancer growth. Losing serine production stops cell division but doesn't kill cancer cells.
Unfortunately, osteosarcoma cells can then quickly adapt and turn to another energy source, said the senior author.
Studying the cells that adapt to being treated with this drug, the researchers revealed a way that the cells' metabolism shifts to try to burn another type of fuel. Without serine, the osteosarcoma cell can't move through its typical metabolic cycle, so parts of that cycle build up. The buildup of these cellular components - which includes fats, other amino acids, and waste products - then activates a central metabolic signaling molecule called mTORC1. Triggering mTORC1 tells the cell to start burning all the built-up products.
So, the researchers added a second drug that blocks mTORC1. Now deprived of both serine and the secondary fuel source, the cancer cells were starved of energy and died.
"When we added an mTORC1 inhibitor, suddenly we could control tumor growth in mice for a prolonged period of time, well past when the cells would adapt to treatment with either drug alone," said first author.
The mTORC1 inhibitor is called perhexiline and has been used since the 1970s to treat angina, or chest pain. More recently, it has been investigated as a treatment for certain types of heart failure.
The researchers studied mice implanted with human osteosarcoma tumors. In mice receiving either drug alone or a control treatment, the tumors increased in volume by almost 800% over less than 30 days. In contrast, in the mice receiving the two-drug combination, the tumors increased in volume by only 75% over 30 days.
"We are still working to optimize these drug treatments, but we hope to be able to take these findings into a clinical trial," the senior author said. "In the future, we would like to add more metabolic therapies so that one day we might be able to eliminate the remaining chemotherapy drugs that these patients will still receive. The ultimate goal is to transform therapy by going after the metabolic properties that are inherent to osteosarcoma and move away from the classic drugs that damage the whole body."
https://medicine.wustl.edu/news/cutting-off-bone-cancers-fuel-supply-offers-innovative-approach-to-treatment-mouse-study-suggests/
https://www.cell.com/cell-reports/fulltext/S2211-1247(20)31667-3
http://sciencemission.com/site/index.php?page=news&type=view&id=publications%2Fmetabolic-compensation&filter=22
Targeting cancer cells' energy source to replace toxic chemo in osteosarcoma
- 1,119 views
- Added
Edited
Latest News
How brains convert sounds t…
By newseditor
Posted 12 May
Mice with traits of Tourett…
By newseditor
Posted 11 May
Intermittent fasting protec…
By newseditor
Posted 11 May
Microfluidic systems resemb…
By newseditor
Posted 11 May
Neurotransmitter classifica…
By newseditor
Posted 11 May
Other Top Stories
Virulent E.coli neutralizes copper by taking it-up!
Read more
New tool to distinguish between viral, bacterial infections
Read more
Plants to produce vaccine against poliovirus
Read more
Leprosy turns the immune system against itself
Read more
Tracking HIV infection
Read more
Protocols
Improved detection of DNA r…
By newseditor
Posted 09 May
Single-cell adhesive profil…
By newseditor
Posted 07 May
Parasympathetic neurons der…
By newseditor
Posted 07 May
Non-invasive measurements o…
By newseditor
Posted 05 May
A validation strategy to as…
By newseditor
Posted 04 May
Publications
Differential representation…
By newseditor
Posted 12 May
Glucose hypometabolism prom…
By newseditor
Posted 12 May
Organellophagy regulates ce…
By newseditor
Posted 12 May
Decoding mitochondria's rol…
By newseditor
Posted 11 May
APOE2 gene therapy reduces…
By newseditor
Posted 11 May
Presentations
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
RNA structure and functions
By newseditor
Posted 19 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar